Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Diabetes en prevención secundaria. iSGLT2 y arGLP1

140 views

Published on

Ponencia presentada por el Dr. Domingo Marzal Martín en el directo online ‘Fármacos que mejoran el pronóstico cardiovascular’, realizado en la Casa del Corazón el 5 de junio de 2018

Published in: Health & Medicine
  • Be the first to comment

Diabetes en prevención secundaria. iSGLT2 y arGLP1

  1. 1. Domingo Marzal Mart�n Madrid, junio 2018 iSGLT-2 & arGLP-1 ABRAMOS EL CORAZ�N A LOS F�RMACOS QUE MEJORAN EL PRON�STICO CARDIOVASCULAR
  2. 2. 1Zinman B, et al. N Engl J Med. 2015; 26;373:2117-28 2Neal B, et al. N Engl J Med. 2017;377:644-57 3Marso SP, et al. N Engl J Med. 2016;375:311-322 4Marso SP, et al. N Engl J Med. 2016;375:1834-44 13% MACE3 3 years 26% MACE4 2 years aGLP-1iSGLT-2 14% MACE1 3 years 14% MACE2 5 years
  3. 3. Bethel MA, et al. Circulation 2018 (in press) Trials design
  4. 4. Bethel MA, et al. Circulation 2018 (in press) Cardiovascular outcomes
  5. 5. McMurray J, et al. Oral Presentation ACC 2018 HFrEF: prevalence of diabetes
  6. 6. Marwick, TH, et al. J Am Coll Cardiol. 2018;71:339-51 Diabetic heart failure
  7. 7. Neal B, et al. N Engl J Med. 2017;377:644-57 Progression of albuminuria Regression of albuminuria
  8. 8. Kosiborod M, et al. Oral Presentation ACC 2018 Hospitalization for Heart Failure
  9. 9. All-Cause Death Kosiborod M, et al. Oral Presentation ACC 2018
  10. 10. study design Marso SP, et al. N Engl J Med. 2016;375:311-322
  11. 11. Primary endpoint CV death, non-fatal MI, or non-fatal stroke Marso SP, et al. N Engl J Med. 2016;375:311-322
  12. 12. All-cause death Marso SP, et al. N Engl J Med. 2016;375:311-322
  13. 13. Time to first microvascular endpoints Marso SP, et al. N Engl J Med. 2016;375:311-322
  14. 14. Recomendaciones de tratamiento de la DM2 en prevenci�n secundaria
  15. 15. Recomendaciones de tratamiento de la DM2 en prevenci�n secundaria

×